ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Rhea-AI Summary
ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025. The company, which previously focused on developing prostate cancer therapies before discontinuing its clinical trials and development programs, announced key shareholder votes.
Shareholders approved setting the board size at seven directors and re-elected David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach. Additional approvals included the re-appointment of Davidson & Company LLP as auditors and a non-binding advisory vote on executive compensation.
Positive
- All proposed board members successfully re-elected
- Shareholder approval received for all agenda items
Negative
- Clinical trials and development programs discontinued
- No active drug development pipeline
News Market Reaction – EPIX
On the day this news was published, EPIX declined 1.78%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO,
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin and Sandy Zweifach to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
David R. Parkinson | 9,131,148 | 98.83 % | 108,123 | 1.17 % |
Richard M. Glickman | 8,823,885 | 95.50 % | 415,386 | 4.50 % |
Franklin M. Berger | 8,807,588 | 95.33 % | 431,683 | 4.67 % |
Scott Requadt | 9,130,637 | 98.82 % | 108,634 | 1.18 % |
Marella Thorell | 9,135,934 | 98.88 % | 103,337 | 1.12 % |
Alex Martin | 9,132,226 | 98.84 % | 107,045 | 1.16 % |
Sandy Zweifach | 9,112,900 | 98.63 % | 126,371 | 1.37 % |
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; and (ii) on a non-binding advisory basis, the compensation of the Company's named executive officers.
Contact Information:
David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302394301.html
SOURCE ESSA Pharma Inc
FAQ
What major decisions were made at EPIX's 2025 Annual General Meeting?
Who are the current board members of ESSA Pharma (EPIX) following the 2025 AGM?
What is the current status of EPIX's clinical trials and development programs?
When did ESSA Pharma (EPIX) hold its 2025 Annual General Meeting?
